Cargando…
Enhancing Anticancer Effect of Gefitinib across the Blood–Brain Barrier Model Using Liposomes Modified with One α-Helical Cell-Penetrating Peptide or Glutathione and Tween 80
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), such as gefitinib, have been demonstrated to effectively treat the patients of extracranial non-small cell lung cancer (NSCLC). However, these patients often develop brain metastasis (BM) during their disease course. The major...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5187798/ https://www.ncbi.nlm.nih.gov/pubmed/27916828 http://dx.doi.org/10.3390/ijms17121998 |
_version_ | 1782486900376862720 |
---|---|
author | Lin, Kuan-Hung Hong, Shu-Ting Wang, Hsiang-Tsui Lo, Yu-Li Lin, Anya Maan-Yuh Yang, James Chih-Hsin |
author_facet | Lin, Kuan-Hung Hong, Shu-Ting Wang, Hsiang-Tsui Lo, Yu-Li Lin, Anya Maan-Yuh Yang, James Chih-Hsin |
author_sort | Lin, Kuan-Hung |
collection | PubMed |
description | Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), such as gefitinib, have been demonstrated to effectively treat the patients of extracranial non-small cell lung cancer (NSCLC). However, these patients often develop brain metastasis (BM) during their disease course. The major obstacle to treat BM is the limited penetration of anticancer drugs across the blood–brain barrier (BBB). In the present study, we utilized gefitinib-loaded liposomes with different modifications to improve gefitinib delivery across the in vitro BBB model of bEnd.3 cells. Gefitinib was encapsulated in small unilamellar liposomes modified with glutathione (GSH) and Tween 80 (SUV-G+T; one ligand plus one surfactant) or RF (SUV-RF; one α-helical cell-penetrating peptide). GSH, Tween 80, and RF were tested by the sulforhodamine B (SRB) assay to find their non-cytotoxic concentrations on bEnd.3 cells. The enhancement on gefitinib across the BBB was evaluated by cytotoxicity assay on human lung adenocarcinoma PC9 cells under the bEnd.3 cells grown on the transwell inserts. Our findings showed that gefitinib incorporated in SUV-G+T or SUV-RF across the bEnd.3 cells significantly reduced the viability of PC9 cells more than that of free gefitinib. Furthermore, SUV-RF showed no cytotoxicity on bEnd.3 cells and did not affect the transendothelial electrical resistance (TEER) and transendothelial permeability of sodium fluorescein across the BBB model. Moreover, flow cytometry and confocal laser scanning microscopy were employed to evaluate the endocytosis pathways of SUV-RF. The results indicated that the uptake into bEnd.3 cells was mainly through adsorptive-mediated mechanism via electrostatic interaction and partially through clathrin-mediated endocytosis. In conclusion, cell penetrating peptide-conjugated SUV-RF shed light on improving drug transport across the BBB via modulating the transcytosis pathway(s). |
format | Online Article Text |
id | pubmed-5187798 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-51877982016-12-30 Enhancing Anticancer Effect of Gefitinib across the Blood–Brain Barrier Model Using Liposomes Modified with One α-Helical Cell-Penetrating Peptide or Glutathione and Tween 80 Lin, Kuan-Hung Hong, Shu-Ting Wang, Hsiang-Tsui Lo, Yu-Li Lin, Anya Maan-Yuh Yang, James Chih-Hsin Int J Mol Sci Article Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), such as gefitinib, have been demonstrated to effectively treat the patients of extracranial non-small cell lung cancer (NSCLC). However, these patients often develop brain metastasis (BM) during their disease course. The major obstacle to treat BM is the limited penetration of anticancer drugs across the blood–brain barrier (BBB). In the present study, we utilized gefitinib-loaded liposomes with different modifications to improve gefitinib delivery across the in vitro BBB model of bEnd.3 cells. Gefitinib was encapsulated in small unilamellar liposomes modified with glutathione (GSH) and Tween 80 (SUV-G+T; one ligand plus one surfactant) or RF (SUV-RF; one α-helical cell-penetrating peptide). GSH, Tween 80, and RF were tested by the sulforhodamine B (SRB) assay to find their non-cytotoxic concentrations on bEnd.3 cells. The enhancement on gefitinib across the BBB was evaluated by cytotoxicity assay on human lung adenocarcinoma PC9 cells under the bEnd.3 cells grown on the transwell inserts. Our findings showed that gefitinib incorporated in SUV-G+T or SUV-RF across the bEnd.3 cells significantly reduced the viability of PC9 cells more than that of free gefitinib. Furthermore, SUV-RF showed no cytotoxicity on bEnd.3 cells and did not affect the transendothelial electrical resistance (TEER) and transendothelial permeability of sodium fluorescein across the BBB model. Moreover, flow cytometry and confocal laser scanning microscopy were employed to evaluate the endocytosis pathways of SUV-RF. The results indicated that the uptake into bEnd.3 cells was mainly through adsorptive-mediated mechanism via electrostatic interaction and partially through clathrin-mediated endocytosis. In conclusion, cell penetrating peptide-conjugated SUV-RF shed light on improving drug transport across the BBB via modulating the transcytosis pathway(s). MDPI 2016-11-29 /pmc/articles/PMC5187798/ /pubmed/27916828 http://dx.doi.org/10.3390/ijms17121998 Text en © 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Lin, Kuan-Hung Hong, Shu-Ting Wang, Hsiang-Tsui Lo, Yu-Li Lin, Anya Maan-Yuh Yang, James Chih-Hsin Enhancing Anticancer Effect of Gefitinib across the Blood–Brain Barrier Model Using Liposomes Modified with One α-Helical Cell-Penetrating Peptide or Glutathione and Tween 80 |
title | Enhancing Anticancer Effect of Gefitinib across the Blood–Brain Barrier Model Using Liposomes Modified with One α-Helical Cell-Penetrating Peptide or Glutathione and Tween 80 |
title_full | Enhancing Anticancer Effect of Gefitinib across the Blood–Brain Barrier Model Using Liposomes Modified with One α-Helical Cell-Penetrating Peptide or Glutathione and Tween 80 |
title_fullStr | Enhancing Anticancer Effect of Gefitinib across the Blood–Brain Barrier Model Using Liposomes Modified with One α-Helical Cell-Penetrating Peptide or Glutathione and Tween 80 |
title_full_unstemmed | Enhancing Anticancer Effect of Gefitinib across the Blood–Brain Barrier Model Using Liposomes Modified with One α-Helical Cell-Penetrating Peptide or Glutathione and Tween 80 |
title_short | Enhancing Anticancer Effect of Gefitinib across the Blood–Brain Barrier Model Using Liposomes Modified with One α-Helical Cell-Penetrating Peptide or Glutathione and Tween 80 |
title_sort | enhancing anticancer effect of gefitinib across the blood–brain barrier model using liposomes modified with one α-helical cell-penetrating peptide or glutathione and tween 80 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5187798/ https://www.ncbi.nlm.nih.gov/pubmed/27916828 http://dx.doi.org/10.3390/ijms17121998 |
work_keys_str_mv | AT linkuanhung enhancinganticancereffectofgefitinibacrossthebloodbrainbarriermodelusingliposomesmodifiedwithoneahelicalcellpenetratingpeptideorglutathioneandtween80 AT hongshuting enhancinganticancereffectofgefitinibacrossthebloodbrainbarriermodelusingliposomesmodifiedwithoneahelicalcellpenetratingpeptideorglutathioneandtween80 AT wanghsiangtsui enhancinganticancereffectofgefitinibacrossthebloodbrainbarriermodelusingliposomesmodifiedwithoneahelicalcellpenetratingpeptideorglutathioneandtween80 AT loyuli enhancinganticancereffectofgefitinibacrossthebloodbrainbarriermodelusingliposomesmodifiedwithoneahelicalcellpenetratingpeptideorglutathioneandtween80 AT linanyamaanyuh enhancinganticancereffectofgefitinibacrossthebloodbrainbarriermodelusingliposomesmodifiedwithoneahelicalcellpenetratingpeptideorglutathioneandtween80 AT yangjameschihhsin enhancinganticancereffectofgefitinibacrossthebloodbrainbarriermodelusingliposomesmodifiedwithoneahelicalcellpenetratingpeptideorglutathioneandtween80 |